Lifetime Costs of Prophylactic Mastectomies and Reconstruction versus Surveillance
Sir:
W e read with great interest the influential article written by Dr. Mattos and associates. 1 In this article, published in the December of 2015 issue of Plastic and Reconstructive Surgery, the authors concluded that lifetime contralateral single-stage prophylactic mastectomy and breast reconstructive surgery costs were up to $2000 lower than surveillance in high-risk breast cancer is completely reconstructed, in patients who have had radiation therapy to the tissue expander or the permanent implant. I prefer to let the final defect establish itself and then use fat transfers to fill in the soft-tissue deficits only in patients with defects that will benefit from the procedure. I also use autologous fat transfers in patients who have lost their implant or tissue expander following radiation therapy. In this scenario, the fat transfers improve the quality of the soft tissues and often allow for replacement of a tissue expander alone or a tissue expander with a latissimus flap. I am quite selective with regard to which patients receive autologous fat transfers. At least 50 percent of patients who undergo breast reconstruction with implants and then receive postmastectomy radiation therapy will have a good to excellent result: thus, these patients do not routinely receive autologous fat transfers. I also prefer not to perform fat grafting at the time of the exchange procedure because one cannot accurately predict what the eventual deficit might be. In theory, it would be great to use fat transfer in all patients, at the time of their exchange, but many of these patients are quite thin and do not have an adequate donor site. I prefer to preserve fat donor sites in the event that they may be needed as a backup option. I fully agree that autologous fat transfer has significantly improved our ability to modify our final results and can provide great improvements in patients with irradiation to their mastectomy sites. 
